Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of August 2026 for Radiopharm Theranostics Limited, a foreign private issuer headquartered in Carlton South, Victoria, Australia. The filing reports on a specific corporate announcement made to the Australian Securities Exchange on August 26, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event-driven disclosure rather than a financial statement.
Material Changes and Operational Updates
- Clinical Trial Progress: The Company announced that it has dosed the first patient in the second cohort of its BetaBart (RV-01) clinical trial.
- Regulatory Status: The Company files annual reports under Form 20-F.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the standard incorporation by reference into the Company's Form F-3 registration statement.
Key Facts for Investor Verification
- Verify the full text of the attached Public Notice (Exhibit 99.1) regarding the BetaBart (RV-01) trial details.
- Confirm the Company's current cash runway and funding status in the most recent Form 20-F, as this 6-K contains no financial data.
- Monitor subsequent filings for safety data or enrollment updates from the second cohort of the BetaBart trial.